With a half-maximum inhibitory concentration in vitro on p110α less than 5 nM, compared to more than 1150 on p110β, alpelisib has demonstrated major antitumor activity in various preclinical models of cancer, notably when associated with PIK3CA alterations [77]. This evidence concerns the gene PIK3CA and cancer.